Partners

anokion

Anokion

Anokion is a leading immune tolerance company advancing novel, antigen-specific treatments for people living with the devastating effects of autoimmune disease. Anokion is strategically progressing its development pipeline based on an industry-leading, novel platform that harnesses the body’s natural tolerance pathways. Initially formed as a spin-off from the Ecole Polytechnique Fédérale de Lausanne (EPFL), the company is funded by leading investors, including Versant Ventures, Novo Ventures, and Novartis Venture Fund.

www.anokion.com

orion

Orion BioScience

Orion BioScience Inc. is an preclinical stage biotechnology company focused on developing our “Soluble Antigen Array’ (or SAgA) technology to intercept and prevent the onset of autoimmune diseases in at risk and early stage patients. Our research into treating multiple sclerosis, neuromyelitis optica, and type-1 diabetes has shown that Orion can develop disease specific immunotherapeutics that can re-tolerize and restore the healthy immune state. The Orion team leverages extensive development experience, and strong clinical relationships, to rapidly progress first-in-class, blockbuster treatments for NMO and T1D into the clinic.

www.orionbioscience.com